Building a strong team of industry experts as clinical programmes progress
- Andrew Mackie, Director and Chief Business Officer
- Gary Bower, Chief Operating Officer
- Christian Girard, Senior Adviser, Regulatory Strategy
20th May 2020 – VasoDynamics Ltd, the pharmaceutical company developing therapies for common complexities in cancer treatment, today announces key appointments to support the management team.
Ningfeng Fiona Li, CEO of VasoDynamics, said:
“With our clinical programmes progressing rapidly and as we build a strong portfolio of clinical candidates, it is vitally important that we have the industry expertise to support the management team. Each appointment brings in depth experience in their field, and all of which combined, will be critical as we build our reputation to provide Oncologists with companion therapies to work alongside cancer treatments, both preventing and treating the side-effects of cancer treatments to enable their patients to lead more fulfilling lives.”
Andrew Mackie, Director and Chief Business Officer
Andrew, a business development consultant, brings over 25 years’ industry experience in pre-clinical research, clinical development and business development, having held at number of senior roles in Lilly, Novartis, Sanofi, MDS, Antisoma and Ergomed. Prior to this, Andrew was Head of Life Sciences at IP Group. His work includes the set up of the clinical development department, transitioning of new molecules into development, management of Antisoma’s strategic alliance with F Hoffman-La Roche and in-licensed new drug leads through partnerships and acquisitions.
Gary Bower, Chief Operating Officer
Gary has over 30 years’ experience in pharmaceutical Research and Development, with the last 20 years spent as a specialist in managing clinical trials. GTE Consultancy Ltd was founded in 2006 to specifically support smaller biotechnology companies with clinical and pre-clinical development, offering expertise and flexibility. Gary has worked on trials at all stages of development, across different indications (primarily in oncology) and geographical areas, working either directly with Biotechs or through CROs, providing a wealth of experience in rapidly adapting to changing circumstances and managing international, cross-functional teams, especially involving the integration of externally outsourced activities.
Christian Girard, Senior Adviser, Regulatory Strategy
Christian Girard, MiM, is a strategy consultant with a focus on value creation in the orphan drug area. Prior to setting up a consulting practice, Christian has held senior leadership roles in Genzyme. He has advised research institutions, tech transfer offices, patient organisations, start-ups companies as well as mature biotechs and industry leaders, and Venture Capital funds. He work has included establishing companies and subsidiaries, dilutive and non-dilutive funding campaigns, monetizing assets, In/Out-licensing R&D programmes, portfolio prioritization, investment opportunities assessments, regulatory strategies and Early Access Programmes. Christian graduated at leading European business school, ESCP-Europe.
For enquiries, please contact:
|Ningfeng Fiona Li, CEO||+44 7969132263
|Mo Noonan, Mo PR Advisory||0787 6444977
Notes to Editors:
VasoDynamics is a UK pharmaceutical development company focused on improving the standard of cancer care globally. Recognising the mounting cost pressures facing healthcare payers all over the world, VasoDynamics is developing a number of cost-effective medicines, all of which target the prevention of debilitating and often dose-limiting complications of cancer therapy, such as chemotherapy- and radiotherapy-induced mucositis, dermatitis and hair-loss. The Company’s proprietary technology platform utilises the different dynamics of normal and cancerous vasculatures to achieve the most effective and patient friendly protections to prevent severe side-effects during cancer treatment.